Q-omics provides the consensus-scored SRMP3 profile across patient tissues and cancer cell-line models. SRMP3 expression is associated with patient survival in 11 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, SRMP3 is differentially expressed in 2, with the highest sampling consensus in BRCA. Additionally, SRMP3 RNA expression shows 6,422 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight UVM, BRCA, and STAD as cancer lineages where SRMP3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SRMP3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SRMP3 survival associations across molecular data types. SRMP3 RNA expression shows survival associations in the most cancer types (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SRMP3 RNA expression–survival associations across cancer types. High SRMP3 expression shows unfavorable associations in UVM, KICH, DLBC, COAD and SKCM, but favorable associations in MESO. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for SRMP3 RNA expression.
This table summarizes SRMP3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for SRMP3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SRMP3 shows higher tumor expression in BRCA and STAD. The BRCA box plot shows higher SRMP3 RNA expression in tumor versus normal tissue (log2 FC = +0.092, t-test p = .039).
This table shows molecular features associated with SRMP3 in patient tissues and cancer cell lines. In patient samples, SRMP3 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
